Shares of LivaNova PLC (NASDAQ:LIVN – Get Rating) have been given a consensus rating of "Buy" by the six analysts that are currently covering the stock, Marketbeat reports. Five analysts have rated the stock with a buy rating. The average 1 year price target among brokerages that have covered the stock in the last year is $90.20.

A number of equities analysts have commented on the company. StockNews.com upgraded LivaNova from a "hold" rating to a "buy" rating in a research note on Friday, September 9th. Needham & Company LLC reduced their target price on LivaNova from $106.00 to $88.00 and set a "buy" rating on the stock in a report on Thursday, August 4th. Finally, The Goldman Sachs Group reduced their target price on LivaNova from $85.00 to $73.00 and set a "buy" rating on the stock in a report on Tuesday, August 16th.

LivaNova Price Performance

LivaNova stock opened at $50.89 on Friday. The stock's fifty day moving average price is $60.41 and its two-hundred day moving average price is $67.56. LivaNova has a one year low of $50.70 and a one year high of $93.89. The company has a debt-to-equity ratio of 0.36, a current ratio of 2.93 and a quick ratio of 2.47. The firm has a market cap of $2.72 billion, a PE ratio of -90.88 and a beta of 0.91.

Institutional Investors Weigh In On LivaNova

Several hedge funds have recently modified their holdings of the company. Sumitomo Mitsui Trust Holdings Inc. acquired a new position in LivaNova during the 1st quarter worth about $64,579,000. P2 Capital Partners LLC acquired a new position in LivaNova during the 4th quarter worth about $56,968,000. Sachem Head Capital Management LP lifted its holdings in LivaNova by 54.2% during the 4th quarter. Sachem Head Capital Management LP now owns 1,734,500 shares of the company's stock worth $151,647,000 after buying an additional 609,500 shares during the period. Loomis Sayles & Co. L P lifted its holdings in LivaNova by 601.5% during the 2nd quarter. Loomis Sayles & Co. L P now owns 601,679 shares of the company's stock worth $37,587,000 after buying an additional 515,914 shares during the period. Finally, Goldman Sachs Group Inc. lifted its holdings in LivaNova by 63.0% during the 1st quarter. Goldman Sachs Group Inc. now owns 993,066 shares of the company's stock worth $81,263,000 after buying an additional 383,973 shares during the period. Institutional investors and hedge funds own 98.89% of the company's stock.

About LivaNova

(Get Rating)

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. It operates through three segments: Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.

Read More

• Get a free copy of the StockNews.com research report on LivaNova (LIVN)
• The Worst May be Over for Target, But is the Stock Safe to Buy?
• Are These Liquid Natural Gas Stocks Ready For An Upside Bounce?
• Two Fun Stocks The Insiders Are Buying
• Novavax Remains a Risk-On Stock in a Risk-Off Market
• 3 Defensive Stocks With 60-Year Dividend Hike Streaks

Receive News & Ratings for LivaNova Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LivaNova and related companies with MarketBeat.com's FREE daily email newsletter.